Current management strategies for CH. Patients with CHIP/CCUS are typically identified incidentally as routine screening for CHIP/CCUS is not currently recommended outside of the context of a well-designed clinical research study. We advise the use of the CHRS to risk stratify patients with CHIP/CCUS into high-, intermediate-, and low-risk groups. All patients with cytopenia should be offered a bone marrow biopsy and cytogenetic profile to rule out underlying MDS. Patients at high risk may be followed up every 3 to 6 months depending on cytopenia burden and the rate of clinical change. Bone marrow biopsies and NGS should be repeated for clinical changes that may indicate progression. These patients are most likely to derive benefit from therapeutic intervention clinical trials designed to prevent malignant transformation and, if interested, may be considered for these studies. Less frequent monitoring is indicated for patients at intermediate and low risk. Bone marrow biopsies should not be performed outside of initial workup of cytopenia or to investigate clinical changes that may be indicative of progression. These patients are statistically unlikely to derive benefit from therapeutic clinical trials designed to prevent malignant transformation, and these patients should not be routinely considered as candidates for these studies. All patients may derive benefit from healthy lifestyle modifications such as smoking cessation, reduction of visceral fat burden, and exercise. Patients with CVD risk factors may derive benefit from preventive cardiology evaluation and/or enrollment on clinical trials to prevent CVD outcomes. A complete review of symptoms should be performed on all patients with CCUS to evaluate for systemic immune and autoinflammatory disease, including VEXAS syndrome. CBC + D, complete blood count with differential; NGS, next-generation sequencing.